Why the study?
Evidence for the effectiveness and safety of third-generation β-blockers other than atenolol as first-line treatment in hypertension remains scarce.
Do third-generation beta-blockers improve cardiovascular outcomes compared to atenolol, ACE inhibitors, or thiazide diuretics as first-line monotherapy in hypertensive patients?
Do third-generation beta-blockers improve cardiovascular outcomes compared to atenolol, ACE inhibitors, or thiazide diuretics as first-line monotherapy in hypertensive patients?
Third-generation beta-blockers offer no cardiovascular outcome advantage over atenolol as first-line hypertension therapy and are associated with a higher risk of stroke compared to ACE inhibitors and thiazide diuretics.
No takes yet. Share an insight, caveat, or question.
β-blockers as first-line hypertension therapy need caution; leaves open comparative effectiveness of third-generation agents beyond atenolol.
You et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: